<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01026610</url>
  </required_header>
  <id_info>
    <org_study_id>BVCL007</org_study_id>
    <nct_id>NCT01026610</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B</brief_title>
  <official_title>A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy and Safety at Week 24 of the Treatment for Selecting Optimal Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety and the antiviral activity of two doses
      of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection
      compared to entecavir 0.5 mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral
      activity against wild-type HBV. LB80380 is undergoing clinical development by LG Life
      Sciences for use in the treatment of chronic HBV infection.

      In this study, the treatment period is 48-week with 24-week of follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HBV DNA level (log10) from baseline</measure>
    <time_frame>At Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable serum HBV DNA</measure>
    <time_frame>At Week 24 or Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with HBeAg seroconversion</measure>
    <time_frame>At Week 24 or Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with ALT normalization</measure>
    <time_frame>At Week 24 or Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment during the whole study period</measure>
    <time_frame>At Week 24 or Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>LB80380 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 90 mg (90 mg + placebo), once daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LB80380 150 mg (60 mg + 90 mg), once daily oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>entecavir 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir 0.5 mg, once daily oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380 90 mg</intervention_name>
    <description>LB80380 90 mg + placebo tablets, once daily, for 48 weeks</description>
    <arm_group_label>LB80380 90 mg</arm_group_label>
    <other_name>LB80380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380 150 mg</intervention_name>
    <description>LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks</description>
    <arm_group_label>LB80380 150 mg</arm_group_label>
    <other_name>LB80380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir 0.5 mg</intervention_name>
    <description>entecavir 0.5 mg tablet, once daily, for 48 weeks</description>
    <arm_group_label>entecavir 0.5 mg</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female or male, 18 to 65 years of age, inclusive

          -  Chronic hepatitis B

          -  Not treated with anti-viral therapeutics including interferon or pegylated interferons
             for more than 12 weeks before Screening

          -  Not treated with anti-viral therapeutics including interferon or pegylated interferons
             6 months within Screening

          -  Compensated chronic hepatitis B

          -  HBeAg positive or HBeAg negative

          -  Elevated serum ALT level (1.2-10 X ULN, inclusive)

        Exclusion Criteria:

          -  Co-infection with hepatitis C or D virus (HCV or HDV) or HIV

          -  Decompensated liver disease

          -  Creatinine clearance (calculated by Cockroft-Gault formula) less than 50 ml/min

          -  Screening alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a
             follow-up ultrasonography performed prior to baseline shows findings indicative of HCC

          -  Treatment with immunomodulatory agent or corticosteroids within 6 months prior to
             study entry.

          -  Pregnancy or breast-feeding

          -  Patient is currently abusing alcohol or illicit drugs

          -  Significant systemic illnesses other than liver diseases

          -  Presence of other causes of liver disease

          -  A history of organ transplantation

        Presence of anti-HBs at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <state>Inchen</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri</city>
        <state>Kyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital of Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008 Oct;17(10):1581-8. doi: 10.1517/13543784.17.10.1581 . Review.</citation>
    <PMID>18808318</PMID>
  </reference>
  <reference>
    <citation>Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, Lai CL. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new antiviral agent for chronic hepatitis B (CHB), in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother. 2009 May;53(5):1779-85. doi: 10.1128/AAC.01290-08. Epub 2009 Feb 17.</citation>
    <PMID>19223649</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2009</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>LB80380</keyword>
  <keyword>treatment-naive</keyword>
  <keyword>entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

